Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers, but further innovations are needed before the technology can reach its full potential. In this whitepaper, we explore the most exciting clinical developments in CAR T-cell therapy, and relate them to limitations of approved therapies, including safety, efficacy and logistics.

Promising developments in the field include innovative approaches to CAR T-cell therapy design and delivery:

• Combining CAR T-cell therapy with other therapies or drugs
• Modified CAR T-cells
• Allogeneic CAR T-cells
• CAR T-cell generation in situ

 We discuss how these innovations could help address pressing research questions:

• How can CAR T-cell therapies be more targeted?
• How can CAR T-cell therapies overcome immunosuppression or evasion?
• How can CAR T-cell therapy be more controlled?
• How can a patient’s response to CAR T-cell therapy be more predictable?
• How can CAR T-cell therapies be easier to manufacture and deliver?